anticoagulants, oral factor Xa inhibitors, apixaban, 2.5 mg twice daily for 30 days
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2011 Dec 8;365(23):2167-77. Epub 2011 Nov 13 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, medical patients The Use of
anticoagulants, oral factor Xa inhibitors, apixaban, 2.5 mg twice daily for 30 days
As Treatment, Acute
Is worse Than
low molecular weight heparin (LMWH), enoxaparin 40 mg/d for 6-14 days
To improve outcomes at 30 days: thromboembolic events were similar (2.7% apixaban VS 3% enoxaparin, p=0.44) and major bleeding increased (0.5% apixaban VS 0.2% enoxaparin, p=0.04)